Observational case series on adalimumab-induced paradoxical hidradenitis suppurativa

Abstract

Although the imputability of TNF blockers in paradoxical HS is still debatable, further research and observation are needed to confirm and distinguish patients with genetic and clinical predisposition in the onset or exacerbation of HS during anti-TNF treatment.

Ustekinumab for skin reactions associated with anti‐tumor necrosis factor‐α agents in patients with inflammatory bowel diseases: A single‐center retrospective study

“…They also have the experience of ustekinumab in their daily practise, and some of them have started the off-label use of ustekinumab in this indication, as shown in various case reports with smaller populations. [9][10][11][12][13]17,18 We report a successful collaboration between dermatologists and gastroenterologists in a large series of 26 IBD patients treated with ustekinumab for severe adverse events or tolerance issues to anti-TNF-a.…”

“…30,31 We did not observe hidradenitis suppurativa, although it has been described as adalimumabinduced in a case series with four patients. 11 Of importance, a switch to ustekinumab was prescribed for one of these patients.…”

“…Ustekinumab is a fully human immunoglobulin G1 kappa monoclonal antibody against interleukin (IL)‐12 and IL‐23 approved for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis. There are now a few reports on the use of ustekinumab for managing anti‐TNF‐α cutaneous adverse reactions, with good results . However, to date, most of them only report small series.…”

“…There are now a few reports on the use of ustekinumab for managing anti-TNF-a cutaneous adverse reactions, with good results. [9][10][11][12][13] However, to date, most of them only report small series. Its possible efficacy in CD patients with paradoxical effects has therefore already been suggested.…”

Development of hidradenitis suppurativa in a patient treated with ustekinumab for her psoriasis: A potential paradoxical reaction?

“…promising results about the effectiveness of ustekinumab in the treatment of HS (Blok et al, 2016;Eisen, 2016;Maarouf, Clark, Lee, & Shi, 2018). Although, paradoxical reactions to adalimumab have been reported (Delobeau et al, 2016;Martina, Campanati, Giuliodori, & Offidani, 2017), there are no reports of HS while on treatment with ustekinumab. We report an interesting case of HS development in a female patient with psoriasis while being treated with ustekinumab.…”